Research Information System
Minerva Cardiology and Angiology, vol.69, no.3, pp.261-268, 2021 (SCI-Expanded)
BaCKgroUNd: Most of the current data regarding the use of bioresorbable scaffolds (BrS) come from everolimus-eluting stent platforms. adverse events with the everolimus-eluting BrSs which are the most comprehensively characterized BRS, hampered the clinical use of other BRS. There is paucity of published data regarding long term use of novolimus-eluting BrS. METHODS: This study sought to evaluate the performance of novolimus-eluting BRS device at midterm follow-up in real world clinical practice. one hundred and forty-four patients (mean age 57.5±9.7 years, 78.5% male) treated with 206 scaffolds between october 2015 and december 2017 were enrolled. a device-oriented composite endpoint (doCe) comprising cardiac death, target vessel myocardial infarction (TV-MI), clinically driven target lesion revascularization (TLR) and rate of scaffold thrombosis were investigated. RESULTS: During a mean follow-up of 33±9 months, DOCE occurred in 9 patients (6.3%) of which cardiac death occurred in 2 patients (1.4%), and clinically driven TLR in 7 patients (4.9%), TV-MI in one patient. Target vessel revascularization (TVR) was observed in nine patients. None of the patients experienced scaffold thrombosis. CONCLUSIONS: The use of novolimus-eluting BRS in this real-world population achieved good clinical outcomes.